Congenital Myasthenic Syndromes: a Clinical and Treatment Approach

Current Treatment Options in Neurology
Constantine FarmakidisMazen M Dimachkie

Abstract

Congenital myasthenia syndromes are clinically and genetically heterogeneous but treatable conditions. Careful selection of drug therapy is paramount as the same drug can be effective, ineffective, and even harmful in different congenital myasthenia syndromes. The purpose of this article is to review current treatment options for these conditions. Next-generation sequencing has accelerated the discovery of new genes and facilitated the description of novel congenital myasthenic syndromes. Retrospective therapy data from these newly identified syndromes has provided additional insight on the management of these conditions. Cholinergic agents, β-adrenergic agonists, and open-channel blockers remain the principal treatment modalities, and their optimal use depends on an accurate genetic diagnosis and the timely clinical recognition of the disease. In particular, pyridostigmine, usually a first-line agent, should be avoided in DOK7, acetylcholinesterase deficiency, and slow-channel congenital myasthenic syndromes. Beta-adrenergic agonists have been recognized as a first-line agent for a number of congenital myasthenic syndromes, particularly DOK7 and acetylcholinesterase deficiency, whereas long-lived open-channel blockers of the a...Continue Reading

References

Mar 1, 1995·Journal of Child Neurology·J S Janas, R J Barohn
Apr 18, 1998·Annals of Neurology·C M Harper, A G Engel
May 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Akira TsujinoAndrew G Engel
May 29, 2003·Neurology·C Michel HarperAndrew G Engel
Jul 13, 2005·Neurology·M Bestue-CardielA G Engel
Mar 31, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew G Engel
Aug 10, 2007·Expert Reviews in Molecular Medicine·Juliane S MüllerHanns Lochmüller
Jul 16, 2008·Annals of Neurology·Duygu SelcenAndrew G Engel
Jul 28, 2009·American Journal of Human Genetics·Caroline HuzéDaniel Hantaï
Oct 20, 2009·Neuromuscular Disorders : NMD·U ScharaH Lochmüller
Jun 30, 2012·American Journal of Human Genetics·Katsiaryna BelayaDavid Beeson
Feb 14, 2013·Brain : a Journal of Neurology·Judith CossinsDavid Beeson
Jun 25, 2013·Neurology·Duygu SelcenAndrew G Engel
Apr 25, 2014·Neurology·Duygu SelcenAndrew G Engel
Apr 22, 2015·Lancet Neurology·A G EngelS M Sine
Aug 25, 2015·Neurology·Pedro M Rodríguez CruzDavid Beeson
May 6, 2016·Journal of Neurology, Neurosurgery, and Psychiatry·Pedro M Rodríguez CruzDavid Beeson
Jun 5, 2016·Brain : a Journal of Neurology·Emily O'ConnorHanns Lochmüller
Jun 28, 2016·Muscle & Nerve·Sumit VermaDurga A Shah
Jul 12, 2016·Muscle & Nerve·Amy C VisserMargherita Milone
Jul 30, 2016·Current Opinion in Neurology·David Beeson
Aug 30, 2016·American Journal of Human Genetics·Stéphanie BauchéSophie Nicole
Sep 21, 2016·Neurology. Genetics·Andrew G EngelC Michel Harper
Feb 9, 2017·Annals of Clinical and Translational Neurology·Xin-Ming ShenAndrew G Engel
May 16, 2017·Neuropediatrics·Grace McMackenHanns Lochmüller
Jan 31, 2018·Annals of the New York Academy of Sciences·Manon LeeJacqueline Palace
Apr 16, 2018·Neurologic Clinics·Perry B Shieh, Shin J Oh

❮ Previous
Next ❯

Citations

Jul 31, 2019·Current Opinion in Neurology·An E Vanhaesebrouck, David Beeson
Jul 16, 2020·Journal of Veterinary Internal Medicine·Thomas MignanMark Lowrie
Apr 2, 2019·Emerging Topics in Life Sciences·Rachel ThompsonHanns Lochmüller
Nov 2, 2019·Expert Opinion on Pharmacotherapy·Carolina BarnettVera Bril
Sep 11, 2019·Journal of Child Neurology·Dana B HarrarPartha S Ghosh
May 16, 2020·Frontiers in Pediatrics·Yixia ZhangQian Zhang
Jan 21, 2021·Journal of Child Neurology·Devin E Prior, Partha S Ghosh
Oct 16, 2020·Neurodegenerative Disease Management·Laura De GiglioElena Maria Pennisi
Mar 6, 2021·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Marie-Céline François-HeudeClaude Cances
Dec 6, 2020·Neurology·Brian D Stephens, Min K Kang
Dec 14, 2019·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Chee Geap TayMeow-Keong Thong
Jul 27, 2021·Frontiers in Pharmacology·Maria I Avrutsky, Carol M Troy
Aug 27, 2021·Internal Medicine·Ping XiaWen Lv

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Disease Therapy

In autoimmune diseases, the immune system responds and attacks self-antigens and damages or impairs the function of the tissues. The treatment for autoimmune diseases often involves immunosuppressive agents, but newer treatments are being investigated. Discover the latest research on autoimmune disease therapy here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

© 2022 Meta ULC. All rights reserved